CRL vs PFE: fair value comparison
Charles River Laboratories International, Inc. and Pfizer Inc. · Updated 2026-09-07
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, CRL currently sits closer to the top of our discount ranking. CRL carries the stronger quality grade.
| CRL | PFE | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $288.50 | $28.45 |
| 12-month range | $165.78–$282.34 | $24.23–$28.55 |
| Sector rank | #99 of 113 Healthcare | #101 of 113 Healthcare |
| Quality grade | C | F |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Expanding |
| Revenue growth | Modest | Declining |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: CRL fair value analysis · PFE fair value analysis